Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Warimpex (29/11/2019)

01.12.2019

Marinomed: Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, achieved several important milestones in the first three quarters of 2019. With the products of the Carragelose® segment, the first causal therapy for colds and flu infections, Marinomed achieved a slight revenue growth of Euro 3.30 mn in the first nine months of 2019 (1-9/2018: Euro 3.23 mn). In order to achieve its long-term growth targets, Marinomed primarily focused on investments in research and development in the first three quarters 2019. These expenses stood at Euro 3.19 mn, significantly higher than in the prior-year period (1-9/2018: Euro 2.11 mn).  The result for the first three quarters 2019 stood at Euro -6.15 mn, after Euro -3.81 mn in the prior-year period. The company expects a continued positive order and sales performance in 2019.
Marinomed Biotech: weekly performance: -0.95%

Warimpex: Warimpex Finanz- und Beteiligungs AG delivered the strongest quarterly results in the company’s history. During the reporting period, the real estate development and investment company generated a profit of Euro 57.5 mn – in comparison, a loss of Euro 6.5 mn was reported for the third quarter of the prior year. These results were largely driven by gains on the disposal of properties, an accounting gain on the purchase of loans of former minority shareholders of a Russian group company, and exchange rate gains. Total revenues rose to Euro 23.3 mn during the first three quarters of 2019, while expenses directly attributable to revenues remained constant at Euro 9.2 mn. “The current financial year is shaping up to be one of the most successful years in the history of Warimpex. We will continue on our successful course, which is shaped by the focus on building up our property portfolio, creating new offerings, and strengthening our earnings potential. We have a number of exciting activities on the agenda, including development projects in the Polish cities of Krakow and Bia?ystok, the refurbishment of the hotel in Darmstadt without disrupting ongoing operations, and the continuing development of AIRPORTCITY St. Petersburg in Russia. All of this makes us optimistic for the future,” said Warimpex CEO Franz Jurkowitsch.
Warimpex: weekly performance: 7.32%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (29/11/2019)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Warimpex (29/11/2019)


01.12.2019


Marinomed: Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, achieved several important milestones in the first three quarters of 2019. With the products of the Carragelose® segment, the first causal therapy for colds and flu infections, Marinomed achieved a slight revenue growth of Euro 3.30 mn in the first nine months of 2019 (1-9/2018: Euro 3.23 mn). In order to achieve its long-term growth targets, Marinomed primarily focused on investments in research and development in the first three quarters 2019. These expenses stood at Euro 3.19 mn, significantly higher than in the prior-year period (1-9/2018: Euro 2.11 mn).  The result for the first three quarters 2019 stood at Euro -6.15 mn, after Euro -3.81 mn in the prior-year period. The company expects a continued positive order and sales performance in 2019.
Marinomed Biotech: weekly performance: -0.95%

Warimpex: Warimpex Finanz- und Beteiligungs AG delivered the strongest quarterly results in the company’s history. During the reporting period, the real estate development and investment company generated a profit of Euro 57.5 mn – in comparison, a loss of Euro 6.5 mn was reported for the third quarter of the prior year. These results were largely driven by gains on the disposal of properties, an accounting gain on the purchase of loans of former minority shareholders of a Russian group company, and exchange rate gains. Total revenues rose to Euro 23.3 mn during the first three quarters of 2019, while expenses directly attributable to revenues remained constant at Euro 9.2 mn. “The current financial year is shaping up to be one of the most successful years in the history of Warimpex. We will continue on our successful course, which is shaped by the focus on building up our property portfolio, creating new offerings, and strengthening our earnings potential. We have a number of exciting activities on the agenda, including development projects in the Polish cities of Krakow and Bia?ystok, the refurbishment of the hotel in Darmstadt without disrupting ongoing operations, and the continuing development of AIRPORTCITY St. Petersburg in Russia. All of this makes us optimistic for the future,” said Warimpex CEO Franz Jurkowitsch.
Warimpex: weekly performance: 7.32%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (29/11/2019)




 

Bildnachweis

Aktien auf dem Radar: S Immo , Addiko Bank , AT&S , Flughafen Wien , Zumtobel , Palfinger , Andritz , DO&CO , Immofinanz , Mayr-Melnhof , Verbund , UBM , BKS Bank Stamm , Fabasoft , AMS , Wolford , EVN , Oberbank AG Stamm , Strabag , Amag , E.ON , Fresenius Medical Care , Vonovia SE , Deutsche Boerse , RWE , HeidelbergCement , Allianz , BASF , Daimler , Continental , adidas.


Random Partner

Kathrein Privatbank
Die Kathrein Privatbank hat sich in besonderem Maße auf die Bedürfnisse von Unternehmern, Unternehmerfamilien und Privatstiftungen spezialisiert. Das Leistungsspektrum umfasst alle für diese Klientel wichtigen Dienstleistungen: Dazu zählen die Beratung bei Gründung und Führung einer Stiftung, bei Nachfolgeregelungen, Vererbung, Schenkung sowie bei Unternehmenskäufen und -verkäufen.

>> Besuchen Sie 54 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten